Determination of a catechol-O-methyltransferase inhibitor, Nitecapone (cas 116313-94-1), in human plasma and urine by liquid chromatography

Add time:08/08/2019    Source:sciencedirect.com

Methods based on reversed-phase liquid chromatography with amperometric detection have been developed for determination of nitecapone, 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione, a COMT inhibitor, in human plasma and urine. Nitecapone was extracted with ethyl acetate—hexane mixtures from plasma after acidification with hydrochloric acid and from urine as the tetrabutylammonium ion-pair of its diphenylborate derivative. The recoveries of both methods exceeded 70% and the relative standard deviations for within-day precision were less than 4% and 8% at 50 ng ml−1 and at the quantitation limits, respectively. The methods are selective, sensitive and precise enough for determination of 4–5 ng ml−1 of nitecapone in plasma and urine and are thus suitable for the kind of pharmacokinetic studies exemplified in this paper.

We also recommend Trading Suppliers and Manufacturers of Nitecapone (cas 116313-94-1). Pls Click Website Link as below: cas 116313-94-1 suppliers

Prev:Protection against alcohol-induced gastric mucosal injury by Nitecapone (cas 116313-94-1)
Next:Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: Effect of Nitecapone (cas 116313-94-1))